AtriCure (NASDAQ:ATRC) Raised to Outperform at Oppenheimer
by The Cerbat Gem
The Cerbat Gem— Oppenheimer upgraded shares of AtriCure (NASDAQ:ATRC – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning, Marketbeat.com reports. They currently have $32.00 target price on the medical device company’s stock. Other research analysts have also recently issued reports about the stock. Stifel Nicolaus […]
The Cerbat Gem—Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $216.00 at Oppenheimer. Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $200.00 to $216.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 53.51% from the stock’s previous close. […]
The Cerbat Gem—Blackbaud (NASDAQ:BLKB) Raised to Buy at StockNews.com. StockNews.com upgraded shares of Blackbaud (NASDAQ:BLKB – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Separately, Robert W. Baird decreased their target price on shares of Blackbaud from $95.00 to $88.00 and set an outperform rating for the company in a research report on Wednesday, […]
The Cerbat Gem—Generac (NYSE:GNRC) PT Raised to $145.00 at Oppenheimer. Generac (NYSE:GNRC – Get Free Report) had its target price hoisted by equities researchers at Oppenheimer from $140.00 to $145.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the technology company’s stock. Oppenheimer’s target price would indicate a potential upside of 8.71% from the company’s previous close. […]